SCHEMBL3013673

SCHEMBL3013673

CCc1ccc(-c2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4OC)CC3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.46
SMN1; SMN2 Q16637 9/20 0.46
MAPT P10636 7/20 0.46
LMNA P02545 4/20 0.46
TSHR P16473 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPK1 P28482 3/20 0.45
NPC1 O15118 8/20 0.44
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
POLB P06746 1/20 0.39
ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3019187 0.93 SMN1; SMN2 (0.44) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL3006072 0.93 SMN1; SMN2 (0.50) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL3014151 0.90 RAB9A (0.53) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL2997805 0.90 SMN1; SMN2 (0.52) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL3005919 0.90 SMN1; SMN2 (0.57) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL3011336 0.90 RAB9A (0.49) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL3015473 0.90 RAB9A (0.48) RAB9ASMN1; SMN2MAPTLMNAMAPK1
SCHEMBL3008132 0.89 SMN1; SMN2 (0.48) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL3002520 0.89 SMN1; SMN2 (0.57) RAB9ASMN1; SMN2MAPTLMNATSHR
SCHEMBL3016507 0.89 RAB9A (0.50) RAB9ASMN1; SMN2MAPTLMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.